AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Activity: Haloprogin works by inhibiting the growth of fungi, including dermatophytes and yeasts, which are responsible for causing skin infections such as ringworm (tinea), athlete's foot (tinea pedis), and jock itch (tinea cruris).
Skin Irritation: Topical application of haloprogin may cause skin irritation, including redness, itching, burning, and stinging at the site of application. Some individuals may experience allergic reactions or contact dermatitis as a result of sensitivity to the medication or its components.
Resistance: Prolonged or repeated use of haloprogin may lead to the development of resistance in fungal strains, making the medication less effective over time. It is important to use haloprogin as directed and to avoid overuse or misuse to minimize the risk of resistance.
Systemic Absorption: While haloprogin is primarily intended for topical use and is not typically absorbed systemically in significant amounts, there is a potential for absorption through the skin, especially if applied to large areas of damaged or inflamed skin. Systemic absorption may increase the risk of adverse effects and drug interactions.
Interaction with Other Medications: Haloprogin may interact with other medications, particularly those applied topically to the same area of skin. Concurrent use of other topical medications, especially corticosteroids or other antifungal agents, should be avoided unless directed by a healthcare professional.
Limited Use: Haloprogin is not commonly used today due to the availability of newer antifungal medications that are more effective and have fewer side effects. It has been largely replaced by other topical antifungal agents such as clotrimazole, miconazole, and terbinafine.
Monitoring: Individuals using haloprogin should be monitored for any signs of adverse reactions or worsening of their skin condition. If symptoms persist or worsen despite treatment, medical attention should be sought.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.1 | 0.3 | 9.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 0.9 | 1 |
| Allergies | 2.2 | 2.6 | -0.18 |
| Allergy to milk products | 0.9 | 1 | -0.11 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 3.2 | 4.7 | -0.47 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.3 | 7 |
| Ankylosing spondylitis | 2.1 | 1.1 | 0.91 |
| Anorexia Nervosa | 1 | 2.4 | -1.4 |
| Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
| Asthma | 2.7 | 1.7 | 0.59 |
| Atherosclerosis | 1.6 | 1.1 | 0.45 |
| Atrial fibrillation | 3.4 | 2.2 | 0.55 |
| Autism | 5.9 | 6.7 | -0.14 |
| Autoimmune Disease | 0.3 | 0.8 | -1.67 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 1 | 1.1 | -0.1 |
| Brain Trauma | 0.3 | 1.4 | -3.67 |
| Cancer (General) | 1.2 | -1.2 | |
| Carcinoma | 1.9 | 1.9 | 0 |
| Celiac Disease | 2.2 | 2.2 | 0 |
| Cerebral Palsy | 0.6 | 1.1 | -0.83 |
| Chronic Fatigue Syndrome | 2.9 | 4.6 | -0.59 |
| Chronic Kidney Disease | 2 | 2.2 | -0.1 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Chronic Urticaria (Hives) | 1.3 | -1.3 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.8 | -1 |
| Cognitive Function | 1.9 | 0.8 | 1.37 |
| Colorectal Cancer | 3.7 | 1.7 | 1.18 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 0.8 | 2.4 | -2 |
| COVID-19 | 5.3 | 9.2 | -0.74 |
| Crohn's Disease | 4.9 | 4.9 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.7 | -1.7 | |
| deep vein thrombosis | 1 | 1.1 | -0.1 |
| Depression | 6.8 | 6.2 | 0.1 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.2 | 1.6 | -7 |
| Endometriosis | 1.9 | 1.4 | 0.36 |
| Epilepsy | 1.3 | 1.5 | -0.15 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 3 | 2.4 | 0.25 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 3.9 | -0.03 |
| gallstone disease (gsd) | 2.2 | 0.8 | 1.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.3 | 3.33 |
| Generalized anxiety disorder | 0.8 | 0.9 | -0.13 |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 1.3 | 2.3 | -0.77 |
| Gulf War Syndrome | 0.3 | 1.5 | -4 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 3.2 | 1.4 | 1.29 |
| Heart Failure | 2.2 | 1.7 | 0.29 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1 | -1 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 3.2 | 4.1 | -0.28 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 1.6 | 0.3 | 4.33 |
| IgA nephropathy (IgAN) | 1 | 3.4 | -2.4 |
| Inflammatory Bowel Disease | 3.1 | 5.9 | -0.9 |
| Insomnia | 1.2 | 1.7 | -0.42 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 3.9 | 3.6 | 0.08 |
| ischemic stroke | 1.3 | 1.1 | 0.18 |
| Liver Cirrhosis | 3.7 | 2.3 | 0.61 |
| Long COVID | 4.7 | 5.5 | -0.17 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | -0.9 | |
| Mast Cell Issues / mastitis | 0.9 | -0.9 | |
| ME/CFS with IBS | 0.6 | 1.7 | -1.83 |
| ME/CFS without IBS | 0.2 | 1.7 | -7.5 |
| Menopause | 0.6 | 0.5 | 0.2 |
| Metabolic Syndrome | 3.6 | 5.2 | -0.44 |
| Mood Disorders | 5.5 | 5 | 0.1 |
| Multiple Sclerosis | 2.2 | 5.2 | -1.36 |
| Multiple system atrophy (MSA) | 0.6 | -0.6 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 1.6 | -1.6 | |
| Neuropathy (all types) | 1 | -1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 3.2 | 0 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 4.9 | 5.1 | -0.04 |
| obsessive-compulsive disorder | 3.4 | 3.1 | 0.1 |
| Osteoarthritis | 1.7 | 0.9 | 0.89 |
| Osteoporosis | 1.1 | 0.9 | 0.22 |
| Parkinson's Disease | 3.6 | 5.9 | -0.64 |
| Polycystic ovary syndrome | 4.7 | 2 | 1.35 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.6 | 0.6 | 0 |
| Primary sclerosing cholangitis | 0.7 | 1.3 | -0.86 |
| Psoriasis | 1.8 | 2.8 | -0.56 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 3.3 | 0.48 |
| Rosacea | 1.1 | 0.5 | 1.2 |
| Schizophrenia | 3.1 | 2.4 | 0.29 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 1 | 3.1 | -2.1 |
| Sleep Apnea | 1.7 | 1.4 | 0.21 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 2.1 | 1.8 | 0.17 |
| Systemic Lupus Erythematosus | 1.9 | 1.4 | 0.36 |
| Tic Disorder | 0.9 | 1.5 | -0.67 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 2.2 | 2.9 | -0.32 |
| Type 2 Diabetes | 5.4 | 5.7 | -0.06 |
| Ulcerative colitis | 3.8 | 5.1 | -0.34 |
| Unhealthy Ageing | 3.8 | 2.2 | 0.73 |
| Vitiligo | 2.3 | 1.3 | 0.77 |
